Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMED-2
- Development stage
- Preclinical
- Lead developer
- Onena Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
OMED-2 is a first-in-class monoclonal antibody currently in preclinical development by Onena Medicines. It is designed to target and neutralize Dual-Specificity Inhibitory Protein 2 (DSIP#2), a member of a novel class of secreted proteins that act as metabolic and growth regulators. Onena's therapeutic strategy involves using antibodies to block DSIPs that are aberrantly expressed in disease states, functioning as "brakes" on normal cellular processes or promoting pathological growth. OMED-2 is being investigated for the treatment of solid tumors, specifically melanoma and prostate cancer, as well as iron-deficient anemias, where DSIP#2 is thought to play a regulatory role in disease progression or metabolic imbalance.
02
Targets
DUSP2 (Proteasome assembly chaperone 1)
Beyond the preview
Go deeper on OMED-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMED-2.